Analyst firms · Raymond James · CMPX
Raymond James CMPX price target and rating history
Compass Therapeutics Inc. (CMPX) · Health Care
Raymond James rates Compass Therapeutics Inc. (CMPX) Mkt Perform with a $9 price target, as of its latest action on Apr 28, 2026. It has published 3 rating actions on CMPX since December 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a CMPX price target in the last 12 months, the median target is $10.
- Current rating
- Mkt Perform
- Price target
- $9
- Median target, all firms
- $10
- Actions on CMPX
- 3
Raymond James price target on CMPX
Every Raymond James rating on CMPX
- Apr 28, 2026
- Jul 1, 2025
- Dec 22, 2021
How other firms rate CMPX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wedbush | Neutral | $1 | Sep 23, 2026 |
| Ladenburg Thalmann | Buy | $5 | Jul 1, 2026 |
| Raymond James | Mkt Perform | Apr 28, 2026 | |
| Craig-Hallum | Buy | $15 | Feb 13, 2026 |
| William Blair | Outperform | Jan 5, 2026 | |
| Citizens JMP | Mkt Outperform | $10 | Dec 3, 2025 |
| Canaccord Genuity | Buy | $10 | Dec 3, 2025 |
| Cantor Fitzgerald | Overweight | Dec 3, 2025 |
Questions about Raymond James and CMPX
- What is Raymond James's price target for CMPX?
- Raymond James's latest stated price target for Compass Therapeutics Inc. (CMPX) is $9, from its action on Jul 1, 2025.
- What is Raymond James's rating on CMPX?
- Raymond James rates CMPX Mkt Perform, a neutral rating, as of Apr 28, 2026.
- When did Raymond James last change its view on CMPX?
- On Apr 28, 2026, Raymond James downgrades to Mkt Perform from Outperform.
- How does Raymond James's CMPX target compare with other analysts?
- Across 5 firms with a CMPX price target in the last 12 months, the median target is $10.
More CMPX rating histories
All Raymond James ratingsCMPX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.